Video
Bleeding risk in patients using Botox treatments and blood thinners
Author(s):
“The notable feature was that the bleeding risk is very small. In our particular group, it was less than 1%,” says Jai Seth, MD.
Video Player is loading.
In this video, Jai Seth, MD, discusses the findings of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.
Related Videos
Study data point to gender disparities in oncology research citations
Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Related Content
